

#### OriGene Technologies, Inc.

9620 Medical Center Dr., Suite 200, Rockville, MD 20850 Phone: 1.888.267.4436 Fax: 301-340-9254 Email: techsupport@origene.com Web: www.origene.com

# **Product Information**

PAPP-A ELISA Kit

Catalog Number: EA101041 Storage Temperature: 2 – 8°C

# Instruction for Use

# THIS KIT IS INTENDED FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

#### 1 INTENDED USE

The **ORIGENE PAPP-A ELISA** is an enzyme immunoassay for the quantitative measurement of Pregnancy associated plasma protein A (PAPP-A) in serum and plasma.

#### 2 PRINCIPLE OF THE TEST

The ORIGENE PAPP-A ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The microtiter wells are coated with a polyclonal anti PAPP-A antibody. An aliquot of patient sample containing endogenous PAPP-A is incubated in the coated well with assay buffer. After incubation the unbound material is washed off. In the second incubation step a sandwich complex is formed with a polyclonal anti PAPP-A antibody peroxidase conjugate. Having added the substrate solution, the intensity of color developed is proportional to the concentration of PAPP-A in the sample.

#### Warnings and Precautions

- 1. This kit is for in Research Use Only. For professional use only.
- 2. All reagents of this test kit which contain human serum or plasma have been tested and confirmed negative for HIV I/II, HBsAg and HCV by FDA approved procedures. All reagents, however, should be treated as potential biohazards in use and for disposal.
- 3. Before starting the assay, read the instructions completely and carefully. <u>Use the valid version of the package insert</u> <u>provided with the kit</u>. Be sure that everything is understood.
- 4. The microplate contains snap-off strips. Unused wells must be stored at 2 °C to 8 °C in the sealed foil pouch and used in the frame provided.
- 5. Pipetting of samples and reagents must be done as quickly as possible and in the same sequence for each step.
- 6. Use reservoirs only for single reagents. This especially applies to the substrate reservoirs. Using a reservoir for dispensing a substrate solution that had previously been used for the conjugate solution may turn solution colored. Do not pour reagents back into vials as reagent contamination may occur.
- 7. Mix the contents of the microplate wells thoroughly to ensure good test results. Do not reuse microwells.
- 8. Do not let wells dry during assay; add reagents immediately after completing the rinsing steps.
- 9. Allow the reagents to reach room temperature (21-26°C) before starting the test. Temperature will affect the absorbance readings of the assay. However, values for the samples will not be affected.
- 10. Never pipet by mouth and avoid contact of reagents and specimens with skin and mucous membranes.
- 11. Do not smoke, eat, drink or apply cosmetics in areas where specimens or kit reagents are handled.





- 12. Wear disposable latex gloves when handling specimens and reagents. Microbial contamination of reagents or specimens may give false results.
- 13. Handling should be done in accordance with the procedures defined by an appropriate national biohazard safety guideline or regulation.
- 14. Do not use reagents beyond expiry date as shown on the kit labels.
- 15. All indicated volumes have to be performed according to the protocol. Optimal test results are only obtained when using calibrated pipettes and microtiterplate readers.
- 16. Do not mix or use components from kits with different lot numbers. It is advised not to exchange wells of different plates even of the same lot. The kits may have been shipped or stored under different conditions and the binding characteristics of the plates may result slightly different.
- 17. Avoid contact with Stop Solution containing 0.5 M H<sub>2</sub>SO<sub>4</sub>. It may cause skin irritation and burns.
- 18. Some reagents contain Proclin 300, BND and/or MIT as preservatives. In case of contact with eyes or skin, flush immediately with water.
- 19. TMB substrate has an irritant effect on skin and mucosa. In case of possible contact, wash eyes with an abundant volume of water and skin with soap and abundant water. Wash contaminated objects before reusing them. If inhaled, take the person to open air.
- 20. Chemicals and prepared or used reagents have to be treated as hazardous waste according to the national biohazard safety guideline or regulation.

# 

### **3 REAGENTS**

#### 3.1 Reagents provided

- 1. *Microtiterwells*, 12x8 (break apart) strips, 96 wells; Wells coated with anti-PAPP-A antibody (polyclonal).
- Standard (Standard 0-5), 6 vials (lyophilized), 0.15 mL; Concentrations: 0; 1; 2.5; 5.0; 15.0; 30.0 μg/mL Conversion: 1 mU/mL = 4.5 mg/L The ORIGENE PAPP-A Standards are comparable with NEQAS approved Reference material for Down Syndrome Screening (U/L, IRP 76/610) See "Preparation of Reagents"; contain 0.015% BND and 0.010% MIT as a preservative.
- Control (low and high), 2 vials (lyophilized), 0.15 mL, For control values and ranges please refer to vial label or QC-Datasheet. see "Preparation of Reagents" Contains 0.015% BND and 0.010% MIT as a preservative.
- 4. *Assay Buffer*, 1 vial, 25 mL, ready to use, contains 0.015% BND and 0.010% MIT as a preservative.
- Enzyme Conjugate 11X concentrate, 1 vial, 1.5 mL, complex containing horseradish peroxidase; see "Preparation of Reagents". Contains 0.03% Proclin, 0.015% BND and 0.010% MIT as a preservative.
- 6. *Conjugate Diluent*, 1 vial, 14 mL, ready to use Contains 0.03% Proclin, 0.015% BND and 0.010% MIT as a preservative.
- Substrate Solution, 1 vial, 14 mL, ready to use, Tetramethylbenzidine (TMB).
- Stop Solution, 1 vial, 14 mL, ready to use, contains 0.5M H<sub>2</sub>SO<sub>4</sub>, Avoid contact with the stop solution. It may cause skin irritations and burns.
- Wash Solution, 1 vial, 30 mL (40X concentrated), see "Preparation of Reagents".
  - \* BND = 5-bromo-5-nitro-1,3-dioxane
    - MIT = 2-methyl-2H-isothiazol-3-one

**Note:** Additional *Standard 0* for sample dilution is available upon request.

# 3.2 Materials required but not provided

- A microtiter plate calibrated reader (450 ± 10 nm)
- Calibrated variable precision micropipettes.
- Absorbent paper.
- Distilled or Deionized water
- Timer (60 min. range).
- Semi logarithmic graph paper or software for data reduction

# 3.3 Storage Conditions

When stored at 2-8°C unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.



Opened reagents must be stored at 2-8°C. Microtiter wells must be stored at 2-8°C. Once the foil bag has been opened, care should be taken to close it tightly again.

Opened kits retain activity for two months if stored as described above.

#### 3.4 Preparation of Reagents

Allow all reagents and required number of strips to reach room temperature prior to use.

#### Standards

Reconstitute the lyophilized contents of the standard vial with 150  $\mu$ L Aqua dest. **Note:** The reconstituted standards are stable for 2 months at 2-8°C.

#### Control

Reconstitute the lyophilized content with 150 µL Aqua dest. and let stand for 10 minutes in minimum. Mix the control several times before use.

Note: The reconstituted control is stable for 2 months at 2-8°C

#### Wash Solution

Add deionized water to the 40X concentrated Wash Solution.

Dilute 30 mL of concentrated *Wash Solution* with 1170 mL deionized water to a final volume of 1200 mL. *The diluted Wash Solution is stable for 2 weeks at room temperature.* 

#### Enzyme Conjugate

30 minutes before use dilute 1.0 ml of concentrated Enzyme Conjugate with 10 ml Conjugate Diluent.

<u>Note:</u> The Enzyme Conjugate has to be **prepared fresh 30 min. before use** and cannot be stored longer than 24 hours. If more than one test run is performed, dilute only the quantity required for each test run.

#### 3.5 Disposal of the Kit

The disposal of the kit must be made according to the national regulations. Special information for this product is given in the Material Safety Data Sheets.

#### 3.6 Damaged Test Kits

In case of any severe damage to the test kit or components, ORIGENE has to be informed in writing, at the latest, one week after receiving the kit. Severely damaged single components should not be used for a test run. They have to be stored until a final solution has been found. After this, they should be disposed according to the official regulations.



#### 4 SPECIMEN COLLECTION AND PREPARATION

Serum or plasma (EDTA-, heparin- or citrate plasma) can be used in this assay.

Do not use hemolytic, icteric or lipemic specimens.

Please note: Samples containing sodium azide should not be used in the assay.

#### 4.1 Specimen Collection

#### Serum:

Collect blood by venipuncture (e.g. Sarstedt Monovette # 02.1388.001), allow to clot, and separate serum by centrifugation at room temperature. Do not centrifuge before complete clotting has occurred. Samples containing anticoagulant may require increased clotting time.

#### Plasma:

Whole blood should be collected into centrifuge tubes containing anticoagulant and centrifuged immediately after collection.

(E.g. for EDTA plasma Sarstedt Monovette – red cap - # 02.166.001;

for Heparin plasma Sarstedt Monovette – orange cap - # 02.165.001;

for Citrate plasma Sarstedt Monovette – green cap - # 02.167.001.)

#### 4.2 Specimen Storage and Preparation

Specimens should be capped and may be stored for up to 5 days at 2-8°C prior to assaying.

If EDTA plasma is stored at 2-8°C, it must be assayed within 48 hours.

Specimens held for a longer time (up to two months) should be frozen only once at -20°C prior to assay. Thawed samples should be inverted several times prior to testing.

#### 4.3 Specimen Dilution

If in an initial assay, a specimen is found to contain more than the highest standard, the specimens can be diluted with *Standard O* and reassayed as described in Assay Procedure.

For the calculation of the concentrations this dilution factor has to be taken into account. <u>Example:</u>

a) dilution 1:10: 10 µL Serum + 90 µL *Standard 0* (mix thoroughly)

b) dilution 1:100: 10 μL dilution a) 1:10 + 90 μL *Standard 0* (mix thoroughly).

# 5 ASSAY PROCEDURE

#### 5.1 General Remarks

- All reagents and specimens must be allowed to come to room temperature before use. All reagents must be mixed without foaming.
- Once the test has been started, all steps should be completed without interruption.
- Use new disposal plastic pipette tips for each standard, control or sample in order to avoid cross contamination.
- Absorbance is a function of the incubation time and temperature. Before starting the assay, it is recommended that
  all reagents are ready, caps removed, all needed wells secured in holder, etc. This will ensure equal elapsed time for
  each pipetting step without interruption.
- As a general rule the enzymatic reaction is linearly proportional to time and temperature.



# 5.2 Test Procedure

Each run must include a standard curve.

All standards, samples, and controls should be run in duplicate. All standards, samples, and controls should be run concurrently so that all conditions of testing are the same.

- 1. Secure the desired number of Microtiter wells in the frame holder.
- 2. Dispense **10** µL of each *Standard, Control* and samples with new disposable tips into appropriate wells.
- Add 100 μl Assay Buffer into each well. Thoroughly mix for 10 seconds. It is important to have a complete mixing in this step.
- 4. Incubate for **30 minutes** at room temperature.
- 5. Briskly shake out the contents of the wells.

Rinse the wells 3 times with diluted *Wash Solution* (400 µL). Strike the wells sharply on absorbent paper to remove residual water droplets.

### Important note:

The sensitivity and precision of this assay is markedly influenced by the correct performance of the washing procedure!

- 6. Dispense **100 μL** diluted *Enzyme Conjugate* (see "Preparation of Reagents") into each well.
- 7. Incubate for **30 minutes** at room temperature.
- Briskly shake out the contents of the wells.
   Rinse the wells 3 times with diluted *Wash Solution* (400 μL per well). Strike the wells sharply on absorbent paper to remove residual droplets.
- 9. Add **100 μL** of *Substrate Solution* to each well.
- 10. Incubate for **15 minutes** at room temperature.
- 11. Stop the enzymatic reaction by adding **50**  $\mu$ L of *Stop Solution* to each well.
- 12. Determine the absorbance (OD) of each well at **450±10 nm** with a microtiter plate reader.
  - It is recommended that the wells be read within 10 minutes after adding the Stop Solution.

# 5.3 Calculation of Results

- 1. Calculate the average absorbance values for each set of standards, controls and samples.
- 2. Construct a standard curve by plotting the mean absorbance obtained from each standard against its concentration with absorbance value on the vertical (Y) axis and concentration on the horizontal (X) axis.
- 3. Using the mean absorbance value for each sample determine the corresponding concentration from the standard curve.
- 4. Automated method: The results in the IFU have been calculated automatically using a 4 PL (4 Parameter Logistics) curve fit. 4 Parameter Logistics is the preferred method. Other data reduction functions may give slightly different results.
- 5. The concentration of the samples can be read directly from this standard curve. Samples with concentrations higher than that of the highest standard have to be further diluted diluted or reported as >  $30 \mu g/mL$ . For the calculation of the concentrations this dilution factor has to be taken into account.

# 

# 5.3.1 Example of Typical Standard Curve

The following data is for demonstration only and cannot be used in place of data generations at the time of assay.

Standard	Optical Units (450 nm)
Standard 0 (0 µg/mL)	0.18
Standard 1 (1 µg/mL)	0.38
Standard 2 (2.5 µg/mL)	0.56
Standard 3 (5 µg/mL)	0.83
Standard 4 (15 μg/mL)	1.44
Standard 5 (30 μg/mL)	1.80

#### 6 QUALITY CONTROL

- Good laboratory practice requires that controls be run with each calibration curve. A statistically significant number of controls should be assayed to establish mean values and acceptable ranges to assure proper performance.
- It is recommended to use control samples according to state and federal regulations. The use of control samples is advised to assure the day to day validity of results.
- The controls and the corresponding results of the QC-Laboratory are stated in the QC certificate added to the kit. The values and ranges stated on the QC sheet always refer to the current kit lot and should be used for direct comparison of the results.
- It is also recommended to make use of national or international Quality Assessment programs in order to ensure the accuracy of the results.
- Employ appropriate statistical methods for analyzing control values and trends. If the results of the assay do not fit to the established acceptable ranges of control materials, results should be considered invalid.
- In this case, please check the following technical areas: Pipetting and timing devices; photometer, expiration dates of reagents, storage and incubation conditions, aspiration and washing methods.

# 7 ASSAY CHARACTERISTICS

#### 7.1 Assay Dynamic Range

The range of the assay is between 0.133  $\mu$ g/mL – 30  $\mu$ g/mL.

#### 7.2 Cross Reactivity

The antibody used for the ORIGENE PAPP-A ELISA is specific for human PAPP-A. There is no cross-reactivity to other species.

No reaction is seen with normal human plasma.

#### 8 LIMITATIONS OF USE

Reliable and reproducible results will be obtained when the assay procedure is performed with a complete understanding of the package insert instruction and with adherence to good laboratory practice. Any improper handling of samples or modification of this test might influence the results.

#### 8.1 Interfering Substances

Hemoglobin (up to 4 mg/mL), Bilirubin (up to 0.5 mg/mL) and Triglyceride (up to 30 mg/mL) have no influence on the assay results.

#### 8.2 Drug Interferences

Until today no substances (drugs) are known to us, which have an influence to the measurement of PAPP-A in a sample.

#### 8.3 High-Dose-Hook Effect

No hook effect was observed in this test up to 300  $\mu$ g/mL of PAPP-A.



# 9 LEGAL ASPECTS

# 9.1 Reliability of Results

The test must be performed exactly as per the manufacturer's instructions for use. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable national standards and/or laws. This is especially relevant for the use of control reagents. It is important to always include, within the test procedure, a sufficient number of controls for validating the accuracy and precision of the test.

The test results are valid only if all controls are within the specified ranges and if all other test parameters are also within the given assay specifications. In case of any doubt or concern please contact ORIGENE.

#### 9.2 Liability

Any modification of the test kit and/or exchange or mixture of any components of different lots from one test kit to another could negatively affect the intended results and validity of the overall test. Such modification and/or exchanges invalidate any claim for replacement.

Claims submitted due to customer misinterpretation of laboratory results are also invalid. In the event of any claim, the manufacturer's liability is not to exceed the value of the test kit. Any damage caused to the test kit during transportation is not subject to the liability of the manufacturer.

#### **10 REFERENCES**

- 1. Spencer K., Scouter V., Tul N., Snijders R., Nicolaides K.H. Ultrasound Obset Gynecol. 1999; 13:1-7
- Sancken U. Deutsches Ärzteblatt 97 3.März 2000, Heft 9:A532-A537
- Bayes-Genis A., Conover C.A., Overgaard M.T., et al. N. Engl. J. Med., Vol.345, No.14, 2001: 1022-1029
- 4. Schaeffer H.-J., Sancken U., Eiben B., Opper C., Jung A. Fetal Diagn Ther. 2001; 16: 437-464
- 5. Qiu-Ping Q., Christiansen M., Oxvig C., Pettersson K., Sottrup-Jensen L., Koch C., Norgaard-Pedersen B. Clinical Chemistry 43:12, 1997; 2323-2332
- Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. Health Technol Assess. 2003; 7(11). First and second trimester antenatal screening for Down's Syndrom: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).
- Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. Ultrasound Obstet Gynecol. 2002 Sep;20(3): 219-25. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.

Version 2, last updated March 6, 2016